Literature DB >> 32553242

C3 Glomerulopathy: Pathogenesis and Treatment.

Syeda Behjat Ahmad1, Andrew S Bomback2.   

Abstract

C3 glomerulopathy (C3G) is a rare set of kidney diseases with 2 patterns: C3 glomerulonephritis (C3GN) and dense deposit disease. Pathogenesis of both diseases is due to complement dysregulation in the alternative pathway. Acquired or genetic alterations of the regulatory proteins of the complement pathway result in C3G. Although the disease is characterized by low C3 levels in serum and C3-dominant staining by immunofluorescence on biopsy, other disease entities such as infection-related glomerulonephritis and masked monoclonal deposits can present similarly. Both the C3GN and dense deposit disease variants of C3G are progressive and recur in transplanted kidneys. Although no direct treatment is available, complement blockers are either available or in the clinical trial phase. This review will survey the pathogenesis of C3GN and current treatment options.
Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complement; Dense deposit disease; Membranoproliferative glomerulonephritis

Mesh:

Substances:

Year:  2020        PMID: 32553242     DOI: 10.1053/j.ackd.2019.12.003

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  6 in total

1.  Mycophenolate Mofetil Treatment of C3 Glomerulopathy.

Authors:  Yonatan Peleg; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-19       Impact factor: 8.237

Review 2.  Novel Insights into Factor D Inhibition.

Authors:  Eleni Gavriilaki; Anna Papakonstantinou; Konstantinos A Agrios
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

Review 3.  Inherited Kidney Complement Diseases.

Authors:  Mathieu Lemaire; Damien Noone; Anne-Laure Lapeyraque; Christoph Licht; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-03       Impact factor: 10.614

Review 4.  Precision medicine for the treatment of glomerulonephritis: a bold goal but not yet a transformative achievement.

Authors:  Richard J Glassock
Journal:  Clin Kidney J       Date:  2021-12-11

5.  Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy.

Authors:  Fernando Caravaca-Fontán; Marta Rivero; Teresa Cavero; Montserrat Díaz-Encarnación; Virginia Cabello; Gema Ariceta; Luis F Quintana; Helena Marco; Xoana Barros; Natalia Ramos; Nuria Rodríguez-Mendiola; Sonia Cruz; Gema Fernández-Juárez; Adela Rodríguez; Ana Pérez de José; Cristina Rabasco; Raquel Rodado; Loreto Fernández; Vanessa Pérez-Gómez; Ana Ávila; Luis Bravo; Natalia Espinosa; Natalia Allende; Maria Dolores Sanchez de la Nieta; Eva Rodríguez; Teresa Olea; Marta Melgosa; Ana Huerta; Rosa Miquel; Carmen Mon; Gloria Fraga; Alberto de Lorenzo; Juliana Draibe; Fayna González; Amir Shabaka; Maria Esperanza López-Rubio; María Ángeles Fenollosa; Luis Martín-Penagos; Iara Da Silva; Juana Alonso Titos; Santiago Rodríguez de Córdoba; Elena Goicoechea de Jorge; Manuel Praga
Journal:  Clin Kidney J       Date:  2022-04-28

6.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.